The unprecedented Ebola outbreak in West Africa has interest surging in the creation of the first drugs and vaccines for the hemorrhagic fever — but a separate report Wednesday highlights the inadequacy of counting on experimental products in the pipeline. In the nearly nine months since the outbreak began, up to 30,000 people could have qualified for some sort of infection-blocking drug or vaccine, Oxford University epidemiologist Oliver Brady calculated in the journal Nature. There have been more than 2,000 cases of Ebola, but the higher total reflects people at varying risk of infection — patients' relatives, health workers, funeral directors and non-medical essential workers in outbreak zones — and comes from a statistical model that Brady created for manufacturers to use as they plan how to increase production of experimental products. Other experimental approaches have gotten more public attention as the World Health Organization said it was ethical to try unapproved drugs and vaccines during the current Ebola outbreak.